Mankind Pharma Reports 20.8% Revenue Growth in Q2FY26 with EBITDA Margin at 25.0%
Mankind Pharma, one of India's largest pharmaceutical companies, has announced its financial results for the second quarter and six months ended 30th September 2025. The company's revenue increased by 20.8% YoY, supported by outperformance in Chronic and BSV consolidation, partially impacted by GST disruption. The chronic segment continued to outperform, while the OTC was impacted due to heavy rains and GST 2.0. The BSV growth initiatives are progressing well, with double-digit sequential growth led by mandate brands. The company remains confident of delivering sustainable long-term growth led by four key pillars - steady base business, fast-growing specialty chronic, high potential OTC business, and super specialty BSV portfolio.
Key Highlights
- Revenue from Operations at INR 3,697 Cr, up by 20.8% YoY
- Domestic revenue at INR 3,184 Cr, up 14.5%, Exports at INR 513 Cr, up 82.6% YoY
- Reported EBITDA margin of 25.0% and PAT margin of 14.1%
- Diluted EPS of INR 12.4 down by 24.2% YoY (FV Re.1)
- CFO to EBITDA ratio was 92% for H1FY26 vs 80% in FY25